Fierce Biotech

FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
BioPharma Dive

FDA places formal hold on two Intellia CRISPR trials

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
TipRanks on MSN

Crispr Therapeutics’ Long-term Study on CAR T Therapies: A Market Game Changer?

Crispr Therapeutics (($CRSP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Long-term Follow-up ...

CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
BioPharma Dive

Intellia pauses two CRISPR drug studies after safety scare

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
Technology Networks

CRISPR Study Reveals Gene Linking Down Syndrome to Heart Disease

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
Fierce Biotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
STAT

Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...